Zovighian Bernard J's Form 4/A amendment
AmendedEdwards Lifesciences Corp (EW) · filed Jun 13, 2024
- Accession no.
- 0000950170-24-073281
- Filed
- Jun 13, 2024
- Rule 10b5-1 plan
- Not checked
- Original filed
- May 7, 2024
This filing lists no transactions. It carries over 5 transactions from the original filing that it did not restate. Open-market purchases total $49.8K.
This amendment restates part of 0001225208-24-005743 (filed May 7, 2024). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zovighian Bernard JCIK 0001665141 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001225208-24-005743 (filed May 7, 2024).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 3, 2024 | Common Stock | FTax withholdingDisposed | −527 | $85.06 | −$44,826.62 | 44,288.9 | Direct | |
| May 4, 2024 | Common Stock | MOption exerciseAcquired | +6,265 | $0.00F1 | $0 | 50,553.9 | Direct | |
| May 4, 2024 | Common Stock | FTax withholdingDisposed | −3,718 | $85.25 | −$316,959.5 | 46,835.9 | Direct | |
| May 6, 2024 | Common Stock | PPurchaseAcquired | +580.26 | $85.74 | +$49,751.49 | 3,267.66 | Indirect |
Derivative securities (Table II)
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 4, 2024 | Common Stock | MOption exerciseDisposed | −6,265 | $0.00 | $0 | 0 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F1
On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Total reflects an acquisition of 580.2601 shares of the Issuer's Common Stock on May 6, 2024 under the Issuer's 401(k) Plan in a transaction exempted by Rule 16b-3, as well as 2,558 shares held under the Issuer's 401(k) Plan that were previously reported as directly held.
Remarks
This amendment to the Form 4 filed on May 7, 2024 by the Reporting Person is filed to remove the reporting of the acquisition of shares described in Footnote 1, as it was an exempt transaction in the Issuer's Common Stock pursuant to Section 16b-3(c) of the Securities Exchange Act of 1934, as amended, and to disclose the number of shares beneficially owned indirectly by the Reporting Person as represented on the most recent statement of the Issuer's 401(k) Plan Administrator.